Death from all causes during treatment (range 6 days to 16 days) · acute ischaemic stroke
Low‐molecular‐weight heparins or heparinoids showed no clear difference in death from all causes during treatment (range 6 days to 16 days) compared with unfractionated heparin (low certainty).
1 finding from 1 review
Death from all causes during · acute ischaemic stroke
Low‐molecular‐weight heparins or heparinoids showed no clear difference in death from all causes during compared with unfractionated heparin (low certainty).
1 finding from 1 review
Deep vein thrombosis · acute ischaemic stroke
Low‐molecular‐weight heparins or heparinoids may leads to lower deep vein thrombosis during treatment period (range 6 days to 16 days) compared with unfractionated heparin (low certainty).
1 finding from 1 review
Pulmonary embolism · acute ischaemic stroke
Low‐molecular‐weight heparins or heparinoids showed no clear difference in pulmonary embolism during treatment period (range 6 days to 16 days) compared with unfractionated heparin (low certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage/haemorrhagic transformation of the cerebral infarct during treatment period (range 6 days to 16 days)⁹ · acute ischaemic stroke
Low‐molecular‐weight heparins or heparinoids showed no clear difference in symptomatic intracranial haemorrhage/haemorrhagic transformation of… compared with unfractionated heparin (low certainty).
1 finding from 1 review
Swallowing ability · dysphagia in acute and subacute stroke
1 finding from 1 review
Death or dependency at end of · dysphagia in acute and subacute stroke
Swallowing therapy showed no clear difference in death or dependency at end of trial compared with placebo (moderate certainty).
1 finding from 1 review
Case fatality · dysphagia in acute and subacute stroke
Swallowing therapy showed no clear difference in case fatality at end of trial compared with placebo (moderate certainty).
1 finding from 1 review
Length of stay (inpatients only) · dysphagia in acute and subacute stroke
1 finding from 1 review
Dysphagia · dysphagia in acute and subacute stroke
Swallowing therapy may leads to lower proportion of participants with dysphagia at end of trial compared with placebo (low certainty).
1 finding from 1 review
Penetration aspiration score · dysphagia in acute and subacute stroke
1 finding from 1 review
Adverse event: chest infection or pneumonia · dysphagia in acute and subacute stroke
It is very uncertain whether swallowing therapy changes adverse event: chest infection or pneumonia compared with placebo (very low certainty).
1 finding from 1 review
Secondary outcome measure: lower extremity function at the end of · patients with improving activities of daily living, and physical and cognitive functioning at the end of follow‐up, in people after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent stroke of any type · stroke and/or TIA
Blood pressure‐lowering drugs (BPLDs) probably leads to lower recurrent stroke of any type compared with placebo or no treatment (moderate certainty).
2 findings from 1 review
Stroke, myocardial infarction, or vascular death · stroke and/or TIA
Blood pressure‐lowering drugs (BPLDs) showed no clear difference in major vascular event (composite of non‐fatal stroke, non‐fatal… compared with placebo or no treatment (high certainty).
1 finding from 1 review
Myocardial infarction · stroke and/or TIA
Blood pressure‐lowering drugs (BPLDs) showed no clear difference in myocardial infarction compared with placebo or no treatment (high certainty).
1 finding from 1 review
Deaths due to vascular events · stroke and/or TIA
Blood pressure‐lowering drugs (BPLDs) leads to lower vascular death compared with placebo or no treatment (high certainty).
1 finding from 1 review
Death by any cause · stroke and/or TIA
Blood pressure‐lowering drugs (BPLDs) showed no clear difference in death by any cause compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Dementia · stroke and/or TIA
Blood pressure‐lowering drugs (BPLDs) showed no clear difference in dementia compared with placebo or no treatment (high certainty).
1 finding from 1 review
Expressive language: naming · adults with aphasia following stroke
It is very uncertain whether summary of findings: SLT changes expressive language: naming (6 months compared with no SLT (follow‐up at 6 months) (very low certainty).
1 finding from 1 review